0.88USD
194.58 MUSD
2.94 BUSD
157.69 M
About Hikma Pharmaceuticals plc.
Sector
CEO
Riad Mishlawi
Headquarters
London
Website
Employees (FY)
9.1 K
Founded
1978
ISIN
GB00B0LCW083
FIGI
BBG000J7M124
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
Is this Hikma's cue for a break out?Will Hikma break out after a 5 year H&S pattern,
now that it's making progress in the Covid-19 vaccine business?
Hikma Pharmaceuticals - Injecting some bullish momentum.Buy Hikma Pharmaceuticals (HIK.L)
Hikma Pharmaceuticals PLC develops, manufactures, and markets pharmaceutical products. The Company offers branded and non-branded generic and in-licensed pharmaceutical products. Hikma Pharmaceuticals serves customers worldwide.
Market Cap: £4.79Billion
The lo
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of HKMPF is 22.33 USD — it has decreased by 7.92% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Hikma Pharmaceuticals plc. stocks are traded under the ticker HKMPF.
Hikma Pharmaceuticals plc. is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
HKMPF stock is 8.60% volatile and has beta coefficient of 0.59. Check out the list of the most volatile stocks — is Hikma Pharmaceuticals plc. there?
HKMPF earnings for the last quarter are 0.89 USD per share, whereas the estimation was 0.78 USD resulting in a 13.72% surprise. The estimated earnings for the next quarter are 0.95 USD per share. See more details about Hikma Pharmaceuticals plc. earnings.
Hikma Pharmaceuticals plc. revenue for the last quarter amounts to 1.30 B USD despite the estimated figure of 1.24 B USD. In the next quarter revenue is expected to reach 1.33 B USD.
Yes, you can track Hikma Pharmaceuticals plc. financials in yearly and quarterly reports right on TradingView.
HKMPF stock has fallen by 7.92% compared to the previous week, the month change is a 4.45% fall, over the last year Hikma Pharmaceuticals plc. has showed a 7.37% increase.
HKMPF net income for the last quarter is 59.94 M USD, while the quarter before that showed 134.84 M USD of net income which accounts for −55.55% change. Track more Hikma Pharmaceuticals plc. financial stats to get the full picture.
Today Hikma Pharmaceuticals plc. has the market capitalization of 4.98 B, it has decreased by 5.24% over the last week.
Hikma Pharmaceuticals plc. dividend yield was 3.17% in 2023, and payout ratio reached 81.97%. The year before the numbers were 2.92% and 66.56% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, HKMPF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Hikma Pharmaceuticals plc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 23, 2024, the company has 9.10 K employees. See our rating of the largest employees — is Hikma Pharmaceuticals plc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Hikma Pharmaceuticals plc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Hikma Pharmaceuticals plc. stock shows the sell signal. See more of Hikma Pharmaceuticals plc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Hikma Pharmaceuticals plc. future price: according to them, HKMPF price has a max estimate of 35.31 USD and a min estimate of 23.73 USD. Read a more detailed Hikma Pharmaceuticals plc. forecast: see what analysts think of Hikma Pharmaceuticals plc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Hikma Pharmaceuticals plc. EBITDA is 682.86 M USD, and current EBITDA margin is 23.72%. See more stats in Hikma Pharmaceuticals plc. financial statements.